Market closed

Quest Diagnostics/$DGX

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Quest Diagnostics

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Ticker

$DGX
Sector
Health Care

Trading on

NYSE

Industry

Health Care Providers & Services
Headquarters
Secaucus, United States

Employees

44,000
Website
www.questdiagnostics.com

DGX Metrics

BasicAdvanced
$17B
20.57
$7.44
0.89
$2.96
1.96%

$17B

0.89

$163.40

$123.04

741K

$2.96

1.254

1.023

89.452

100.708

38.88%

6.69%

5.65%

13.22%

20.571

1.784

2.52

-4.88

16.636

1.93%

1.96%

2.60%

11.56%

-4.77%

-23.53%

6.94%

What the Analysts think about DGX

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Quest Diagnostics stock.

DGX Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

DGX Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

DGX News

AllArticlesVideos
Augurex Life Sciences and Quest Diagnostics Collaborate to Improve Rheumatoid Arthritis Diagnosis and Management

Augurex Life Sciences and Quest Diagnostics Collaborate to Improve Rheumatoid Arthritis Diagnosis and Management

Business Wire·2 months ago
Quest Diagnostics Has Massive Secular Tailwinds And A Strong Base

Quest Diagnostics Has Massive Secular Tailwinds And A Strong Base

Seeking Alpha·3 months ago
Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat

Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat

Seeking Alpha·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $DGX

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

Jan29
Quest Diagnostics
Dividend·Payment
$0.75
Per share

FAQs

What’s the current market cap for Quest Diagnostics stock?

Quest Diagnostics (DGX) has a market cap of $17B as of January 15, 2025.

What is the P/E ratio for Quest Diagnostics stock?

The price to earnings (P/E) ratio for Quest Diagnostics (DGX) stock is 20.57 as of January 15, 2025.

Does Quest Diagnostics stock pay dividends?

Yes, the Quest Diagnostics (DGX) stock pays dividends to shareholders. As of January 15, 2025, the dividend rate is $2.96 and the yield is 1.96%. Quest Diagnostics has a payout ratio of 38.88% on a trailing twelve-month basis.

When is the next Quest Diagnostics dividend payment date?

The next Quest Diagnostics (DGX) dividend payment is scheduled for January 29, 2025.

What is the beta indicator for Quest Diagnostics?

Quest Diagnostics (DGX) has a beta rating of 0.89. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.